Oramed Pharmaceuticals Price to Free Cash Flow Ratio 2011-2024 | ORMP

Oramed Pharmaceuticals price to free cash flow ratio from 2011 to 2024. Price to free cash flow ratio can be defined as

Oramed Pharmaceuticals Price to Free Cash Flow Ratio 2011-2024 | ORMP

Oramed Pharmaceuticals price to free cash flow ratio from 2011 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$203.2B
Stryker (SYK)$148.2B
Boston Scientific (BSX)$133.1B
EssilorLuxottica (ESLOY)$113.5B
Medtronic (MDT)$109B
Haleon (HLN)$42.9B
Lonza Group Ag (LZAGY)$42.1B
GE HealthCare Technologies (GEHC)$37.7B
ResMed (RMD)$35B
Terumo (TRUMY)$29.2B
Koninklijke Philips (PHG)$24.4B
Zimmer Biomet Holdings (ZBH)$22.1B
Insulet (PODD)$18.4B
Baxter (BAX)$16.6B
Smith & Nephew SNATS (SNN)$11.2B
BellRing Brands (BRBR)$9.5B
Bio-Rad Laboratories (BIO)$9B
Demant (WILYY)$8.3B
Lantheus Holdings (LNTH)$5.5B
TG Therapeutics (TGTX)$4.7B
Haemonetics (HAE)$4.3B
ICU Medical (ICUI)$4.2B
Prestige Consumer Healthcare (PBH)$4.1B
Perrigo (PRGO)$3.7B
Envista Holdings (NVST)$3.5B
Neogen (NEOG)$3.3B
Agios Pharmaceuticals (AGIO)$3.1B
Shandong Weigao Medical Polymer (SHWGF)$3B
GN Store Nord (GNNDY)$2.8B
QuidelOrtho (QDEL)$2.6B